<code id='917F0111A4'></code><style id='917F0111A4'></style>
    • <acronym id='917F0111A4'></acronym>
      <center id='917F0111A4'><center id='917F0111A4'><tfoot id='917F0111A4'></tfoot></center><abbr id='917F0111A4'><dir id='917F0111A4'><tfoot id='917F0111A4'></tfoot><noframes id='917F0111A4'>

    • <optgroup id='917F0111A4'><strike id='917F0111A4'><sup id='917F0111A4'></sup></strike><code id='917F0111A4'></code></optgroup>
        1. <b id='917F0111A4'><label id='917F0111A4'><select id='917F0111A4'><dt id='917F0111A4'><span id='917F0111A4'></span></dt></select></label></b><u id='917F0111A4'></u>
          <i id='917F0111A4'><strike id='917F0111A4'><tt id='917F0111A4'><pre id='917F0111A4'></pre></tt></strike></i>

          Home / explore / focus

          focus


          focus

          author:hotspot    Page View:5343

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In